CANCER CHEMOTHERAPY USING AZABICYCLO COMPOUND Russian patent published in 2024 - IPC A61K31/437 A61K39/395 A61K45/00 A61P35/00 A61P37/04 A61P43/00 C07D471/04 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to an anticancer agent for treating a tumour in a patient with cancer, comprising 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridine-1-yl}benzamide or a salt thereof and an immune checkpoint molecule regulator, which are administered in combination, where the immune checkpoint molecule regulator is an anti-PD-1 antibody, anti-PD-L1 antibody or anti-CTLA-4 antibody and wherein the cancer is selected from a group consisting of colon cancer, gastric cancer, gastrointestinal stromal tumour, lung cancer and breast cancer. Invention also relates to use of 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazole[3,4-b]pyridin-1-yl}benzamide or a salt thereof, to a method of treating a tumour in a patient with cancer, a method for improving the anti-tumour effect of the immune checkpoint molecule regulator in a patient with cancer.

EFFECT: improved anticancer action without serious side effects provided by combination 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridine-1-yl}benzamide or a salt thereof and an immune checkpoint molecule regulator, which is an anti-PD-1 antibody, an anti-PD-L1 antibody or an anti-CTLA-4 antibody.

21 cl, 4 dwg, 2 tbl, 3 ex